about
Triphala and its active constituent chebulinic acid are natural inhibitors of vascular endothelial growth factor-a mediated angiogenesisEarly sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary studyIn vitro Anti-Proliferative Effect of Tephrosia purpurea on Human Hepatocellular Carcinoma Cells.Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling.Cord colitis syndrome: a cause of granulomatous inflammation in the upper and lower gastrointestinal tractInhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.Sorafenib in melanoma.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell linesProcyanidin B2 3,3″-di-O-gallate inhibits endothelial cells growth and motility by targeting VEGFR2 and integrin signaling pathwaysFractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).Cyclodextrin polymers as nanocarriers for sorafenib.Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model.Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.
P2860
Q21090869-D5AFCCC9-D7D1-4666-A41F-B3078C6D740BQ28482219-28570364-BCC9-4D6C-9B84-2CCEDD787930Q32177679-D0ACF533-C50D-412A-95DE-E2517CB45DA9Q34238619-8FAD5CD4-11D2-4CC3-B534-D4E88AACBB9FQ34347234-F2276919-8DA2-4A79-A53E-44766352CDC8Q34758477-1A19D32E-A20F-4C5A-BF58-F7198CD08F99Q37990977-5CF9DF66-2192-4354-9DB8-0B541A569BDDQ38201503-BDE7FDB3-EAC6-4BCC-94A0-970AFB0D7AF9Q38292288-A97B4D6A-E136-46B8-9E41-CA408907BAD5Q41858794-E916AF43-C8F5-4190-BDB4-735E0A2BA030Q44252023-AA155222-48CF-4323-9D0E-0E1FBF982D8DQ47806297-8EC46037-7EEC-4E82-9855-6CA46A6343B6Q54580043-4655F2AE-1607-4C11-B5E9-89B0CCEAC2BFQ54963896-C3868FE5-FD2D-496C-B2A9-7BE2308D446DQ54987295-F86B9BE4-FD99-4F51-AE83-1D220BA16A7BQ55115766-CF5656BF-552D-44B0-89F1-539EE97F401F
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Toxicity of sorafenib: clinical and molecular aspects.
@en
Toxicity of sorafenib: clinical and molecular aspects.
@nl
type
label
Toxicity of sorafenib: clinical and molecular aspects.
@en
Toxicity of sorafenib: clinical and molecular aspects.
@nl
prefLabel
Toxicity of sorafenib: clinical and molecular aspects.
@en
Toxicity of sorafenib: clinical and molecular aspects.
@nl
P2093
P2860
P1476
Toxicity of sorafenib: clinical and molecular aspects.
@en
P2093
Benoit Blanchet
Bertrand Billemont
Bertrand Knebelmann
Camille Francès
François Goldwasser
Hélène Garrigue
Laure Cabanes
Romain Coriat
Stéphane Barete
P2860
P304
P356
10.1517/14740330903510608
P407
P577
2010-03-01T00:00:00Z